LIPOSOMAL FORMULATION FOR ORAL ADMINISTRATION OF GLUTATHIONE (REDUCED) AND/OR METHYLCOBALAMINE FOR DISEASES RELATED TO GLUTATHIONE DEFICIENCY AND DEFICIENCY OF THE METHIONINE REMETHYLATION PATHWAY
The invention proposes the use of reduced glutathione encapsulated in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to improve symptoms in disease states related to diminished function of the methylation pathway such as autism, other neurodegenerative diseases and abnormalities of neurotransmitter levels in urine or blood. The invention also proposes combining liposomal encapsulated methylcobalamine, and/or liposomal encapsulated Insulin Growth Factor 1 (IGF-1) with liposomal reduced glutathione to accomplish such improvement.
1 . A pharmaceutical composition affecting the production and utilization of neurotransmitters, particularly in the SAM cycle, comprising:
reduced glutathione in a liposomal formulation and methylcobalamine in a liposomal formulation.
2 . A pharmaceutical composition affecting the production and utilization of neurotransmitters, particularly in the SAM cycle, comprising:
reduced glutathione in a liposomal formulation and IGF-1 in a liposomal formulation.
3 . A pharmaceutical composition affecting the production and utilization of neurotransmitters, particularly in the SAM cycle, comprising:
reduced glutathione in a liposomal formulation, methylcobalamine in a liposomal formulation, and IGF-1 in a liposomal formulation.
4 . The composition according to claims 1 , 2 , 3 or 4 , further comprising:
a therapeutic dose of selenium.
5 . A method of treatment of neurotransmitter deficiency state in mammalian patients, comprising:
administration of reduced glutathione in a liposomal formulation.
6 . A method of treatment of neurotransmitter deficiency state in mammalian patients, comprising:
administration of reduced glutathione in a liposomal formulation and methylcobalamine in a liposomal formulation.
7 . A method of treatment of neurotransmitter deficiency state in mammalian patients, comprising:
administration of reduced glutathione in a liposomal formulation and IGF-1 in a liposomal formulation.
8 . A method of treatment of neurotransmitter deficiency state in mammalian patients, comprising:
administration of reduced glutathione in a liposomal formulation, administration of methylcobalamine in a liposomal formulation, and IGF-1 in a liposomal formulation.
9 . A method of treatment of the clinical conditions accompanying vitamin B-12 deficiency, or homocysteine cycle defects, or cysteine generation defects in mammalian patients, comprising:
administration of reduced glutathione in a liposomal formulation, followed by methylcobalamine in a liposomal formulation.
10 . A method of treatment of the clinical conditions accompanying vitamin B-12 deficiency, or homocysteine cycle defects, or cysteine generation defects in mammalian patients, comprising:
administration of reduced glutathione in a liposomal formulation, followed by methylcobalamine in a liposomal formulation and IGF-1 in a liposomal formulation.
11 . A method of treatment of autism and related neurodevelopmental disorders in mammalian patients, comprising:
administration of reduced glutathione in a liposomal formulation, followed by methylcobalamine in a liposomal formulation.
12 . A method of treatment of autism and related neurodevelopmental disorders in mammalian patients, comprising:
administration of reduced glutathione in a liposomal formulation, followed by methylcobalamine in a liposomal formulation and IGF-1 in a liposomal formulation.
13 . The method according to claims 5 , 6 , 7 , 8 , 9 , 10 , 11 , or 12 further comprising:
administering a therapeutic dose of Selenium.
14 . The method according to claims 5 , 6 , 7 , 8 , 9 , 10 , 11 , or 12 , further comprising the following step:
assessing the level of at least one neurotransmitter in a mammalian patient.
15 . The method according to claims 5 , 6 , 7 , 8 , 9 , 10 , 11 , or 12 , further comprising the following step:
assessing the level of at least one neurotransmitter in a mammalian patient; and
administering a therapeutic dose of Selenium.